Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Jan 18:14:1329541.
doi: 10.3389/fneur.2023.1329541. eCollection 2023.

Time-restricted ketogenic diet in amyotrophic lateral sclerosis: a case study

Affiliations
Case Reports

Time-restricted ketogenic diet in amyotrophic lateral sclerosis: a case study

Matthew C L Phillips et al. Front Neurol. .

Abstract

Amyotrophic lateral sclerosis (ALS) is an incurable neurodegenerative disorder. The most devastating variant is bulbar-onset ALS, which portends a median survival of 24 months from the onset of symptoms. Abundant evidence indicates that neuron metabolism and mitochondrial function are impaired in ALS. Metabolic strategies, particularly fasting and ketogenic diet protocols, alter neuron metabolism and mitochondria function in a manner that may mitigate the symptoms of this disorder. We report the case of a 64-year-old man with a 21-month history of progressive, deteriorating bulbar-onset ALS, with an associated pseudobulbar affect, who implemented a time-restricted ketogenic diet (TRKD) for 18 months. During this time, he improved in ALS-related function (7% improvement from baseline), forced expiratory volume (17% improvement), forced vital capacity (13% improvement), depression (normalized), stress levels (normalized), and quality of life (19% improvement), particularly fatigue (23% improvement). His swallowing impairment and neurocognitive status remained stable. Declines were measured in physical function, maximal inspiratory pressure, and maximal expiratory pressure. Weight loss was attenuated and no significant adverse effects occurred. This case study represents the first documented occurrence of a patient with ALS managed with either a fasting or ketogenic diet protocol, co-administered as a TRKD. We measured improved or stabilized ALS-related function, forced expiratory volume, forced vital capacity, swallowing, neurocognitive status, mood, and quality of life. Measurable declines were restricted to physical function, maximal inspiratory pressure, and maximal expiratory pressure. Now over 45 months since symptom onset, our patient remains functionally independent and dedicated to his TRKD.

Keywords: amyotrophic lateral sclerosis; energy metabolism; fasting; ketogenic diet; metabolic strategy; mitochondria dysfunction; motor neuron disease; neurodegeneration.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Patient timeline.
Figure 2
Figure 2
Mean monthly blood glucose and ketone (beta-hydroxybutyrate) levels during the time-restricted ketogenic diet (TRKD). Error bars indicate standard error.

Similar articles

Cited by

References

    1. Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. (2019) 32:771–6. 10.1097/WCO.0000000000000730 - DOI - PMC - PubMed
    1. Arthur KC, Calvo A, Price TR, Geiger JT, Chió A, Traynor BJ. Projected increase in amyotrophic lateral sclerosis from 2015 to 2040. Nat Commun. (2016) 7:12408. 10.1038/ncomms12408 - DOI - PMC - PubMed
    1. Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol. (2020) 27:1918–29. 10.1111/ene.14393 - DOI - PMC - PubMed
    1. Goutman SA, Hardiman O, Al-Chalabi A, Chió A, Savelieff MG, Kiernan MC, et al. . Recent advances in the diagnosis and prognosis of amyotrophic lateral sclerosis. Lancet Neurol. (2022) 21:480–93. 10.1016/S1474-4422(21)00465-8 - DOI - PMC - PubMed
    1. Blasco H, Lanznaster D, Veyrat-Durebex C, Hergesheimer R, Vourch P, Maillot F, et al. . Understanding and managing metabolic dysfunction in amyotrophic lateral sclerosis. Expert Rev Neurother. (2020) 20:907–19. 10.1080/14737175.2020.1788389 - DOI - PubMed

Publication types